China SXT Pharmaceuticals, Inc.
corporate_fare Company Profile
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for SXTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-28, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for SXTC spans 6-K, 424B5, F-3, 20-F.
Recent high-impact activity:
- China SXT Resets Financing Floor Price to $0.20 After 1-for-80 Reverse Split
- China SXT Prices $9M Registered Direct Offering with Highly Dilutive Zero-Price Warrants
- $9M Direct Offering at $2.00 Deepens Dilution for Cash-Strapped China SXT
- Registers Resale of 157.5M Shares from Highly Dilutive $30M Pre-Paid Purchase Financing
- Secures up to $30M in Highly Dilutive 'Pre-Paid Purchase' Financing
Financial Snapshot
Dilution Risk
High riskFiling-implied dilution signals for SXTC, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.
$9M Registered Direct Offering Priced · Zero-Price Warrants Could Add 63M Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
SXTC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.